Method of Inhibiting the Transport of L-glutamate
Background: L-Glutamate is one of the most abundant excitatory neurotransmitters in the mammalian brain and, as such, is responsible for many synaptic transmissions in the central nervous system. Yet, while other neurotransmitters are degraded rapidly to terminate the transmitter signal, L-glutamate is removed from the synaptic cleft by high affinity transport. Furthermore, little is known about the conformational requirements of substrate binding to this transport system. Technology: Researchers at the University of California, Irvine, have developed novel compounds that are potent and selective inhibitors of the high affinity transport of L-glutamate. These compounds will be used to investigate the mechanism of the transport system and will be evaluated for their therapeutic efficacy for the treatment of various neurological disorders such as ischemia, hypoglycemia, epilepsy, Huntington's disease, and Alzheimer's disease.
Type of Offer:
« More Biotech Patents« More Medical Patents